The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.
Verazza, S., Davì, S., Consolaro, A., Insalaco, A., Gerloni, V., Cimaz, R., et al. (2017). Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL, 15(S1), 125-125.
Data di pubblicazione: | 2017 |
Titolo: | Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept |
Autori: | |
Citazione: | Verazza, S., Davì, S., Consolaro, A., Insalaco, A., Gerloni, V., Cimaz, R., et al. (2017). Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL, 15(S1), 125-125. |
Rivista: | |
Nome del convegno: | 23rd Paediatric Rheumatology European Society Congress |
Anno del convegno: | 28 September – 01 October |
Luogo del convegno: | Genova |
Settore Scientifico Disciplinare: | Settore MED/38 - Pediatria Generale E Specialistica |
Appare nelle tipologie: | 1.05 Abstract in atti di convegno pubblicato in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
PRES2016_MaggioMC_et_al_P216.pdf | PRES2016_etanercept | Versione Editoriale | Open Access Visualizza/Apri |